| Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia RJ Kreitman, C Dearden, PL Zinzani, J Delgado, L Karlin, T Robak, ... Leukemia 32 (8), 1768-1777, 2018 | 255 | 2018 |
| Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia M Konopleva, PF Thall, CA Yi, G Borthakur, A Coveler, C Bueso-Ramos, ... Haematologica 100 (7), 927, 2015 | 108 | 2015 |
| Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia F Ravandi, C Arana Yi, JE Cortes, M Levis, S Faderl, G Garcia-Manero, ... Leukemia 28 (7), 1543-1545, 2014 | 103 | 2014 |
| Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis C Arana Yi, CS Tam, S Verstovsek Future Oncology 11 (5), 719-733, 2015 | 69 | 2015 |
| Reverse Warburg effect in a patient with aggressive B-cell lymphoma: is lactic acidosis a paraneoplastic syndrome UE Martinez-Outschoorn, D Whitaker-Menezes, M Valsecchi, ... Semin Oncol 40 (4), 403-18, 2013 | 48 | 2013 |
| Advances in the therapy of chronic idiopathic myelofibrosis C Arana-Yi, A Quintás-Cardama, F Giles, D Thomas, A Carrasco-Yalan, ... The oncologist 11 (8), 929-943, 2006 | 35 | 2006 |
| Maturing clinical profile of IMGN779, a next-generation CD33-targeting antibody-drug conjugate, in patients with relapsed or refractory acute myeloid leukemia JE Cortes, DJ DeAngelo, HP Erba, E Traer, N Papadantonakis, ... Blood 132, 26, 2018 | 30 | 2018 |
| Secondary cytogenetic abnormalities in core-binding factor AML harboring inv (16) vs t (8; 21) SY Han, K Mrózek, J Voutsinas, Q Wu, EA Morgan, H Vestergaard, ... Blood advances 5 (10), 2481-2489, 2021 | 28 | 2021 |
| Therapy-related myelodysplastic syndrome and acute myeloid leukemia following treatment of acute myeloid leukemia: possible role of cytarabine C Arana-Yi, AMW Block, SN Sait, LA Ford, M Barcos, MR Baer Leukemia research 32 (7), 1043-1048, 2008 | 26 | 2008 |
| Core‐binding factor acute myeloid leukemia with t (8; 21): risk factors and a novel scoring system (I‐CBF it) C Ustun, E Morgan, EEM Moodie, S Pullarkat, C Yeung, S Broesby‐Olsen, ... Cancer medicine 7 (9), 4447-4455, 2018 | 22 | 2018 |
| Avapritinib versus placebo in indolent systemic mastocytosis J Gotlib, M Castells, HO Elberink, F Siebenhaar, K Hartmann, ... NEJM evidence 2 (6), EVIDoa2200339, 2023 | 20 | 2023 |
| Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients N Gangat, O Karrar, M Iftikhar, K McCullough, IM Johnson, M Abdelmagid, ... American Journal of Hematology 99 (2), 193-202, 2024 | 14 | 2024 |
| Real-world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts N Gangat, K McCullough, I Johnson, A Al-Kali, KH Begna, MM Patnaik, ... American journal of hematology 97 (6), E214-E216, 2022 | 14 | 2022 |
| Sarcoidosis mimicking metastatic bone disease in head and neck cancer CA Yi, P McCue, M Rosen, M Machtay, R Axelrod, GJ Morris Semin Oncol 40, 529-534, 2013 | 13 | 2013 |
| A randomized phase II trial of CX-01 with standard therapy in elderly patients with acute myeloid leukemia (AML). T Kovacsovics, MY Levy, RJ Cook, JE Kolitz, P Westervelt, WB Donnellan, ... Journal of Clinical Oncology 37 (15_suppl), 7001-7001, 2019 | 12 | 2019 |
| Molecular pathways in clonal hematopoiesis: from the acquisition of somatic mutations to transformation into hematologic neoplasm C Gaulin, K Kelemen, C Arana Yi Life 12 (8), 1135, 2022 | 9 | 2022 |
| Results from ongoing phase 2 trial of SL-401 in patients with advanced, high-risk myeloproliferative neoplasms including chronic myelomonocytic leukemia MM Patnaik, V Gupta, JR Gotlib, HE Carraway, M Wadleigh, GJ Schiller, ... Blood 128 (22), 4245, 2016 | 9 | 2016 |
| Spontaneous resolution of untreated diffuse large B‐cell lymphoma of maxillary bone after incisional biopsy L Flatow‐Trujillo, K Win, A Jencks, L Andritsos, C Arana Yi Clinical Case Reports 7 (11), 2082-2086, 2019 | 8 | 2019 |
| Ruxolitinib in the treatment of polycythemia vera: An update on health-realted quality of life and patient-reported outcomes AY Cingam, Flatow-Trujillo, Andritsos Journal of blood medicine 10, 381-390, 2019 | 8 | 2019 |
| Comparing outcomes of patients with secondary AML: treatment-related MDS/AML, AML secondary to myeloproliferative neoplasms (t-MPN), and AML with prior malignancies CYA Yi, HM Kantarjian, G Garcia-Manero, WG Wierda, G Borthakur, ... Blood 120 (21), 3557, 2012 | 8 | 2012 |
Dr. Mrinal PatnaikAssociate Professor of Medicine, Mayo Clinic College of Medicine, Rochester, MinnesotaVerified email at mayo.edu
